After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter.  Why?  Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same – Twitter and Square.

Well, medtech’s version of Jack Dorsey might be Duke Rohlen.  Duke led FoxHollow Technologies through an IPO and then later solid it to ev3 for close to $800M.  He also founded CV Ingenuity and sold it to Covidien for approximately $300M.  Now, similar to Jack Dorsey, Duke is leading 2 early stage companies at the same time – Spirox and Advanced Cardiac Therapeutics.

In this interview with Duke Rohlen, CEO of both Spirox and Advanced Cardiac Therapeutics, we learn about the strategies and tactics he employed that led to the successful exits of FoxHollow Technologies and CV Ingenuity for a combined total of over $1 billion

Interview Highlights with Duke Rohlen

  • Why Duke and the CV Ingenuity team felt bittersweet after selling to Covidien for $300M.
  • Why the CV Ingenuity team pursued a US-only strategy.
  • Why CV Ingenuity managed their clinical trials internally vs. working with an outside CRO.
  • Duke’s previous relationships with the leadership at ev3 (now Medtronic) and why they were critical to closing the CV Ingenuity deal with Covidien.
  • How Duke secured a unique $300M collaboration with Merck while serving as President of Fox Hollow Technologies.
  • The major lessons Duke has learned raising money for 4 different medical device companies.
  • How Duke is able to successfully lead two early-stage medtech companies at the same time.
  • Duke’s favorite book, the CEO he’s closely following right now, and the advice he’d give to his 30-yr. old self.

Listen to the Interview with Duke Rohlen

Read the Interview with Duke Rohlen

Download a copy of the interview transcript right here.

About Duke Rohlen

Duke Rohlen serves as Chairman and CEO of Spirox, Inc. and Chairman and CEO of Advanced Cardiac Therapeutics.  Prior to these roles, Duke served as founder and CEO of CV Ingenuity where he raised $30.0 million of venture capital prior to selling the company to Covidien (now Medtronic) in 2013 for ~$300.0 million. Prior to CV Ingenuity, Duke served in a variety of roles at FoxHollow Technologies prior to being named President. Duke helped drive annual sales to ~$200.0 million, helped the company through an IPO, conceived of and structured a $300.0 million collaboration with Merck Pharmaceuticals, and ultimately led the sale of the company to EV3 (now Medtronic) for $780.0 million in 2008. Prior to working at FoxHollow, Duke held senior management positions at two other medical technology companies and served as an entrepreneur-in-residence at the private equity firm, Alta Partners.

You May Like These Articles

  • Recent
  • Featured
  • Related

Why Your Product Should Generate Revenue Versus Reduce Costs: Interview with Cognetivity CEO Sina Habibi

Cognetivity Neurosciences Co-founder and CEO Sina Habibi discusses the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser.

Demonstrating Value with Robust Clinical Trial Data: Interview with Miracor Medical CEO Olivier Delporte

Miracor Medical CEO Olivier Delporte explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.

How to Convince Investors, Payers, and Patients Your Device is Worth the Cost: Interview with Bone Health Technologies CEO Laura Yecies

Bone Health Technologies CEO Laura Yecies shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do.

The Importance of Going All In On Your Medtech Business: Interview with SynerFuse Co-Founders Justin Zenanko and Greg Molnar

SynerFuse Co-Founders Justin Zenanko and Greg Molnar share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.

Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular

In this interview, Bruce Shook discusses medical device insurance coverage and reimbursement, as well as advice for other healthcare entrepreneurs that need to raise money.

Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger

In this interview, the legendary Dr. John Simpson shares what drew him to the field of cardiology, his approach to building a medtech team, and why knowing your strengths and limitations is key to making a difference in the lives of others.

After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

In this interview with Duke Rohen, he discusses how he successfully led two early-stage medtech companies at the same time and the major lessons he learned raising money for 4 different medical device companies.

Having a Heart Attack? There’s an App for That! The Incredible Story of How Dr. David Albert Brought the ECG iPhone App to Market

In this interview with Dr. David Albert, we learn about his incredible journey in bringing the first iPhone ECG app to market with AliveCor.

Why Your Product Should Generate Revenue Versus Reduce Costs: Interview with Cognetivity CEO Sina Habibi

Cognetivity Neurosciences Co-founder and CEO Sina Habibi discusses the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser.

Demonstrating Value with Robust Clinical Trial Data: Interview with Miracor Medical CEO Olivier Delporte

Miracor Medical CEO Olivier Delporte explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.

How to Convince Investors, Payers, and Patients Your Device is Worth the Cost: Interview with Bone Health Technologies CEO Laura Yecies

Bone Health Technologies CEO Laura Yecies shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do.

The Importance of Going All In On Your Medtech Business: Interview with SynerFuse Co-Founders Justin Zenanko and Greg Molnar

SynerFuse Co-Founders Justin Zenanko and Greg Molnar share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.